SAB BIOTHERAPEUTICS INC (SABS) Fundamental Analysis & Valuation

NASDAQ:SABS • US78397T2024

Current stock price

3.7 USD
+0.22 (+6.32%)
Last:

This SABS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. SABS Profitability Analysis

1.1 Basic Checks

  • SABS had negative earnings in the past year.
  • SABS had a negative operating cash flow in the past year.
  • SABS had negative earnings in 4 of the past 5 years.
  • SABS had negative operating cash flow in 4 of the past 5 years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 0 20M -20M -40M

1.2 Ratios

  • SABS has a better Return On Assets (-7.42%) than 82.91% of its industry peers.
  • Looking at the Return On Equity, with a value of -8.46%, SABS belongs to the top of the industry, outperforming 86.80% of the companies in the same industry.
Industry RankSector Rank
ROA -7.42%
ROE -8.46%
ROIC N/A
ROA(3y)-41.66%
ROA(5y)-36.58%
ROE(3y)-67.38%
ROE(5y)-61.39%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. SABS Health Analysis

2.1 Basic Checks

  • SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SABS has more shares outstanding
  • SABS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for SABS has been reduced compared to a year ago.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • SABS has an Altman-Z score of 5.35. This indicates that SABS is financially healthy and has little risk of bankruptcy at the moment.
  • SABS's Altman-Z score of 5.35 is fine compared to the rest of the industry. SABS outperforms 73.98% of its industry peers.
  • SABS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • SABS's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. SABS outperforms 44.08% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 5.35
ROIC/WACCN/A
WACC9.54%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 9.46 indicates that SABS has no problem at all paying its short term obligations.
  • The Current ratio of SABS (9.46) is better than 78.45% of its industry peers.
  • SABS has a Quick Ratio of 9.46. This indicates that SABS is financially healthy and has no problem in meeting its short term obligations.
  • SABS has a better Quick ratio (9.46) than 78.45% of its industry peers.
Industry RankSector Rank
Current Ratio 9.46
Quick Ratio 9.46
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. SABS Growth Analysis

3.1 Past

  • SABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.45%, which is quite impressive.
  • Measured over the past years, SABS shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -60.74% on average per year.
  • SABS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)42.45%
EPS 3YN/A
EPS 5Y-60.74%
EPS Q2Q%71.45%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • SABS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.11% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y62.76%
EPS Next 2Y33.38%
EPS Next 3Y21.32%
EPS Next 5Y18.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. SABS Valuation Analysis

4.1 Price/Earnings Ratio

  • SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year SABS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • SABS's earnings are expected to grow with 21.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.38%
EPS Next 3Y21.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SABS Dividend Analysis

5.1 Amount

  • SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SABS Fundamentals: All Metrics, Ratios and Statistics

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (4/30/2026, 10:42:06 AM)

3.7

+0.22 (+6.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-09
Earnings (Next)05-07
Inst Owners53.48%
Inst Owner Change0%
Ins Owners0.88%
Ins Owner Change-0.01%
Market Cap247.64M
Revenue(TTM)N/A
Net Income(TTM)-12.82M
Analysts85.71
Price Target9.69 (161.89%)
Short Float %4.78%
Short Ratio4.98
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.86%
Min EPS beat(2)-72.65%
Max EPS beat(2)70.94%
EPS beat(4)2
Avg EPS beat(4)2.68%
Min EPS beat(4)-72.65%
Max EPS beat(4)70.94%
EPS beat(8)4
Avg EPS beat(8)9.62%
EPS beat(12)6
Avg EPS beat(12)-35.01%
EPS beat(16)10
Avg EPS beat(16)-14.1%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.33%
PT rev (3m)1.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.01%
EPS NY rev (1m)-28.69%
EPS NY rev (3m)-27.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS2.26
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -7.42%
ROE -8.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-41.66%
ROA(5y)-36.58%
ROE(3y)-67.38%
ROE(5y)-61.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 30.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.46
Quick Ratio 9.46
Altman-Z 5.35
F-Score3
WACC9.54%
ROIC/WACCN/A
Cap/Depr(3y)14.24%
Cap/Depr(5y)169.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.45%
EPS 3YN/A
EPS 5Y-60.74%
EPS Q2Q%71.45%
EPS Next Y62.76%
EPS Next 2Y33.38%
EPS Next 3Y21.32%
EPS Next 5Y18.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.23%
EBIT Next 3Y-20.67%
EBIT Next 5YN/A
FCF growth 1Y-31.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.57%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SABS.


What is the valuation status for SABS stock?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


Can you provide the profitability details for SAB BIOTHERAPEUTICS INC?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 2 / 10.


Can you provide the financial health for SABS stock?

The financial health rating of SAB BIOTHERAPEUTICS INC (SABS) is 5 / 10.